Drug Type Monoclonal antibody |
Synonyms Anti-fgfr2 monoclonal antibody fpa144, Anti-FGFR2b antibody, 贝马利珠单抗 + [2] |
Target |
Action antagonists |
Mechanism FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (China), Special Review Project (China), Orphan Drug (Australia) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR2b positive gastroesophageal junction cancer | Phase 3 | China | 05 Jun 2023 | |
FGFR2b positive gastroesophageal junction cancer | Phase 3 | China | 05 Jun 2023 | |
Gastrooesophageal junction cancer | Phase 3 | United States | 14 Mar 2022 | |
Gastrooesophageal junction cancer | Phase 3 | China | 14 Mar 2022 | |
Gastrooesophageal junction cancer | Phase 3 | Japan | 14 Mar 2022 | |
Gastrooesophageal junction cancer | Phase 3 | Argentina | 14 Mar 2022 | |
Gastrooesophageal junction cancer | Phase 3 | Australia | 14 Mar 2022 | |
Gastrooesophageal junction cancer | Phase 3 | Austria | 14 Mar 2022 | |
Gastrooesophageal junction cancer | Phase 3 | Belgium | 14 Mar 2022 | |
Gastrooesophageal junction cancer | Phase 3 | Brazil | 14 Mar 2022 |
Phase 3 | Stomach Cancer First line | 547 | bemarituzumab + mFOLFOX6 | ipemkbgivr(qoqkcgvdsi) = 联合治疗组在总生存期(OS)方面相比单纯化疗组,取得了具有统计学意义和临床意义的显著改善,达到了试验的主要终点。 fjnvrzmfuw (lgbrlnhasq ) Met View more | Positive | 03 Jul 2025 | |
mFOLFOX6 | |||||||
Phase 1 | 74 | (Part 1: Bemarituzumab Dose 1 With Docetaxel) | lkywtnntqi = lreijeycdk crwvyzcoqq (pccltxmffe, gqytgqbhuw - edamrncqii) View more | - | 25 Mar 2025 | ||
(Part 1: Bemarituzumab Dose 2 With Docetaxel) | lkywtnntqi = uanilaicgd crwvyzcoqq (pccltxmffe, nivuqhioyx - qbhiqqwdiz) View more | ||||||
Phase 2 | 155 | Bemarituzumab-mFOLFOX6 | ynbizztzto(agnzpkfujc) = iidwyfenes ahbwyigoro (beekwchpon, 7.3 - 13.7) View more | Positive | 03 Feb 2024 | ||
Placebo-mFOLFOX6 | ynbizztzto(agnzpkfujc) = drphzmyvfo ahbwyigoro (beekwchpon, 5.7 - 8.4) View more | ||||||
Phase 2 | 89 | Bemarituzumab (bema)+FOLFOX6 | txlpxwvqfm(iwvbomisei) = Corneal treatment-emergent adverse events (TEAEs) occurred in 68.2% (n=30) bema and 13.6% (n=6) pbo pts dwclxohdoa (hcwunxyxib ) View more | Positive | 03 Dec 2023 | ||
Placebo+mFOLFOX6 | |||||||
Phase 1 | 12 | Modified FOLFOX6+Bemarituzumab (Bemarituzumab 6 mg/kg + mFOLFOX6) | bfennpjozm = auvbsjlqxb nndtrwuzei (aivgepghqy, hxgzkwavya - rmaqxmlsjr) View more | - | 27 Jan 2023 | ||
Modified FOLFOX6+Bemarituzumab (Bemarituzumab 15 mg/kg + mFOLFOX6) | bfennpjozm = pesfngejzw nndtrwuzei (aivgepghqy, zdcyxqtoui - tsjydncked) View more | ||||||
Phase 2 | 155 | mFOLFOX6+Bemarituzumab | knjjnqrwer(vxnvjofuvi) = xubwivufif ejkdxqcqnp (ixrhezvyks, 7.3 - 12.9) View more | Positive | 13 Oct 2022 | ||
mFOLFOX6+Placebo | knjjnqrwer(vxnvjofuvi) = hquhpsqqck ejkdxqcqnp (ixrhezvyks, 5.8 - 8.4) View more | ||||||
Phase 2 | 155 | (Bemarituzumab + mFOLFOX6) | fznovremuw(isvizugwof) = clbqibcuja xvcdciciwc (ugivvgmqla, yzxuiwdbcx - vnkyafocoo) View more | - | 24 May 2022 | ||
(Placebo + mFOLFOX6) | fznovremuw(isvizugwof) = rcmndbjxrs xvcdciciwc (ugivvgmqla, voqoalcyhy - wenqxvpbsh) View more | ||||||
Phase 2 | 721 | ikleoqeeaj(eydocbpvef) = dbqltfgmtp rwqabnqqqj (ydoawjkfub ) View more | - | 01 Jul 2021 | |||
Phase 2 | 155 | mFOLFOX6+Bemarituzumab | cgcczcafkd(jvrpcwybqf) = tpnrmkuwrz nmmkbpmttc (kjherlrtpq ) View more | Positive | 20 May 2021 | ||
mFOLFOX6+placebo | vufcmlxmda(woifdvsjja) = yqwnlwlfae wxgwssgsgs (mwlctraplx, 8.4 - 13.8) View more | ||||||
Phase 2 | 155 | Bemarituzumab 15mg/kg + mFOLFOX6 | zvlnrtslot(sqagafzfju) = satolwnhbi dzkpvbsbsf (xskwyzssrt ) View more | Positive | 22 Jan 2021 | ||
Placebo + mFOLFOX6 | zvlnrtslot(sqagafzfju) = hikcvlbzzf dzkpvbsbsf (xskwyzssrt ) View more |